Crescita Therapeutics (CTX) Q3 2024 earnings summary

Executive summary

• Q3-2024 revenue rose 18.5% year-over-year to $3,594,000, driven by organic and inorganic growth in Skincare and higher Licensing revenue from Pliaglis international launches.

• Net loss improved to $(1,036,000) from $(1,282,000) year-over-year; Adjusted EBITDA loss narrowed to $(681,000) from $(988,000).

• Gross margin increased to 54.7% from 49.4% year-over-year, reflecting favorable product mix and lower obsolescence charges.

• Cash and cash equivalents at quarter-end were $8,438,000, down $574,000, mainly due to equipment investments.

Financial highlights

• Revenue for Q3-2024 was $3,594,000, up $561,000 from Q3-2023; nine-month revenue was $12,678,000, down $119,000 year-over-year.

• Gross profit for Q3-2024 was $1,967,000, up $468,000; gross margin rose to 54.7% from 49.4%.

• Operating expenses increased to $3,139,000 from $2,880,000, mainly due to consulting, partnership, and acquisition-related costs.

• Net loss for Q3-2024 was $(1,036,000), an improvement of $246,000 year-over-year.

• Adjusted EBITDA loss improved to $(681,000) from $(988,000) year-over-year.

Outlook and guidance

• Management expects continued improvement in the Manufacturing segment as new equipment is integrated and new long-term supply agreements are fulfilled.

• Focus remains on increasing sales and margins in existing segments and securing a new U.S. partner for Pliaglis.

• Anticipates launch of MicronJet in Canada in early 2025 following regulatory approval.